Sucralfate pp 191-196 | Cite as

Duodenal Ulcer Therapy, “Acid Rebound,” and Early Relapse

  • I. N. Marks
  • G. O. Young


It is generally accepted that duodenal ulcers (DU) recur within a year in 75-90% of patients following healing with an HZ-receptor antagonist (H2RA). Relapse rates following initial treatment with colloidal bismuth agents are appreciably, and often significantly, lower than those following initial treatment with an H2RA, and a similar short-term advantage has been reported in most 3- to 6-month follow-up studies in patients healed initially with sucralfate. The reason for the trend toward lower relapse rates following ulcer healing with mucosal protective agents is not clear. Attention has been drawn to differences in the quality of ulcer healing following treatment with an H2RA and the mucosal protective agents, and the antimicrobial effect of colloidal bismuth agents against H. pylori-and the possible effect of sucralfate on these organisms is clearly pertinent. A third possibility relates to the concept of increased parietal cell sensitivity following treatment with an H2RA. This review will focus on acid secretory changes following DU healing with sucralfate and H2RAs, and an attempt will be made to link these with the liability to early relapse.


Duodenal Ulcer Acid Secretion Ulcer Healing Early Relapse Duodenal Ulcer Healing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lam SK, Koo J: Gastrin sensitivity in duodenal ulcer. Gut 26:485–490, 1985. Study confirming increased parietal cell sensitivity in patients with an active duodenal ulcer.PubMedCrossRefGoogle Scholar
  2. 2.
    Achord JL: Gastric pepsin and acid secretion in patients with acute and healed duodenal ulcer. Gastroenterology 81:15–18, 1981. Study suggesting that acid secretion decreases on duodenal ulcer healing.PubMedGoogle Scholar
  3. 3.
    Aadland E, Berstad A: Parietal and chief cell sensitivity to histamine and pentagastrin stimulation before and after cimetidine treatment in healthy subjects. Scand J Gastroenterol 14:933–938, 1979.PubMedGoogle Scholar
  4. 4.
    Frislid K, Aadland E, Berstad A: Augmented post-prandial gastric secretion due to exposure to ranitidine in healthy subjects. Scand J Gastroenterol 21:119–122, 1986.PubMedCrossRefGoogle Scholar
  5. 5.
    Nwokolo CU, Smith JTL, Pounder RE: Rebound intragastric hyperacidity occurs following dosing with cimetidine, nizatidine and famotidine. Gastroenterology 96:A369, 1989.Google Scholar
  6. 6.
    Prewett EJ, Hudson M, Nwokolo CU, et al: Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 100:873–877, 1991. Studies in control subjects showing acid rebound following treatment with various H2-receptor blockers.PubMedGoogle Scholar
  7. 7.
    Jones DB, Howden CW, Burget DW, et al: Alteration of H2-receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2-antagonist. Gut 29:890–893, 1988.PubMedCrossRefGoogle Scholar
  8. 8.
    Johnston DA, Marks IN, Young GO, et al: Maintenance treatment with ranitidine and sucralfate does not affect acid secretory responses. S Afr Med J 78:A353, 1990.Google Scholar
  9. 9.
    Fullarton GM, McLaughlan G, Macdonald A, et al: Rebound nocturnal hypersecretion after 4 weeks H2-antagonist therapy. Gut 30:449–454, 1989.PubMedCrossRefGoogle Scholar
  10. 10.
    Fullarton GM, Macdonald AMI, McColl KEL: Rebound hypersecretion after H2-antagonist withdrawal—A comparative study with nizatidine, ranitidine and famotidine. Aliment Pharm Ther 5:391–398, 1991.CrossRefGoogle Scholar
  11. 11.
    Wilder-Smith DH, Halter F, Merke HS: Tolerance and rebound hyperacidity in DU patients. Gut 31:A600, 1990. Studies in patients with duodenal ulcer in remission using different parameters of acid secretion and showing conflicting results following treatment with variable doses of H2RAs.Google Scholar
  12. 12.
    Aadland E, Berstad A: Parietal and chief cell sensitivity to pentagastrin stimulation before and after cimetidine treatment for duodenal ulcer. Scand J Gastroenterol 14:111–114, 1979.PubMedCrossRefGoogle Scholar
  13. 13.
    Savarino V, Mela GS, Zentilin P, et al: Lack of gastric acid rebound after stopping successful short-term course of nizatidine in duodenal ulcer patients. Am J Gastroenterol 86:281–284, 1991.PubMedGoogle Scholar
  14. 14.
    Marks IN, Young GO, Tigler-Wybrandi NA, et al: Acid secretory response and parietal cell sensitivity in patients with duodenal ulcer before and after treatment with sucralfate or ranitidine. Am J Med 86(suppl 6A):145–147, 1989.PubMedCrossRefGoogle Scholar
  15. 15.
    Johnston DA, Marks IN, Young GO, et al: Duodenal ulcer healing and acid secretory responses to modified sham-feeding and pentagastrin stimulation. Aliment Pharm Ther 4:403–410, 1990.CrossRefGoogle Scholar
  16. 16.
    Kummer A, Johnston DA, Marks IN, et al: Changes in nocturnal acid secretion on duodenal ulcer healing with ranitidine and sucralfate. Gut 33:175–178, 1992.PubMedCrossRefGoogle Scholar
  17. 17.
    Johnston DA, Marks IN: Short-term relapse rates after duodenal ulcer healing. S Afr J Cont Med 8:999–1002, 1990. Studies examining the effect of H2RAs in patients with active duodenal ulcer using different parameters of acid secretion. Acid rebound was noted only in the study in which nocturnal acid secretion was measured.Google Scholar
  18. 18.
    Marks IN, Johnston DA, Young GO: Acid secretory changes and early relapse following duodenal ulcer healing with ranitidine or sucralfate. Am J Med 91(suppl 2A):95–101, 1991.CrossRefGoogle Scholar
  19. 19.
    Yanaka A, Muto H: Increased parietal cell responsiveness to tetragastrin in patients with recurrent duodenal ulcer. Dig Dis Sci 33(11):1459–1465, 1988. Studies documenting the relationship between persistent elevation of parietal cell sensitivity on duodenal cell healing and early relapse.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press 1995

Authors and Affiliations

  • I. N. Marks
    • 1
  • G. O. Young
    • 1
  1. 1.Gastrointestinal Clinic and Department of MedicineUniversity of Cape Town and Groote Schuur Hospital, ObservatorySouth Africa

Personalised recommendations